We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Routine Shifting of Intravenous Drips Unnecessary

By HospiMedica International staff writers
Posted on 20 Sep 2010
Small intravenous devices (IVDs) commonly used in the hand or arm do not need to be re-sited routinely every three days, according to a new study.

Researchers at Griffith University (Nathan, Australia), Gippsland Medical School (Churchill, Australia), and other institutions conducted a randomized controlled trial involving a total of 362 patients (603 IVDS) that were randomized to have IVDs replaced on clinical indication (185 patients) or following a routine change every 3 days (177 patients). More...
The IVDs were inserted and managed by the general hospital medical and nursing staff. The primary endpoint was a composite of IVD complications: phlebitis, infiltration, occlusion, accidental removal, local infection, and device-related bloodstream infection.

The results showed that IVD complication rates were 68 per 1,000 IVD days in the clinically indicated group, compared to 66 per 1,000 IVD days in the routine replacement group. The time to first complication per patient did not differ between groups, and there were no local infections or IVD-related bloodstream infections in either group. Intravenous (IV) therapy duration did not differ between groups, but more IVDs were placed per patient in the routine replacement than the clinical indication group, with significantly higher hospital costs per patient. The study was published on September 10, 2010, in BMC Medicine, a publication of BioMed Central.

"Recommended timelines for routine re-site have been extended over the past three decades from 24 to 72 hours. Currently, 72- to 96-hour re-site is recommended,” said lead author Professor of Nursing Claire Rickard, Ph.D., R.N. "Even with these extended durations, such policies still cause increased workload in hospitals, where the task of removing and replacing well-functioning IVDs generally falls to busy nursing and junior medical staff.”

According to the study, the average duration of IV therapy is 5-6 days and many catheters can remain complication-free for this period. A policy of re-site on clinical indication would mean that one of every two patients would need a single cannula to receive treatment, whereas a 3-day change policy would result in only one in five patients having this scenario, with the rest requiring multiple cannulations, and therefore additional pain and inconvenience.

Related Links:
Griffith University
Gippsland Medical School




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.